Skip to main content
. 2020 Apr 2;11(4):973–996. doi: 10.1002/jcsm.12554

Figure 3.

Figure 3

VM‐M3 Develop Prolonged Systemic Inflammation. (A) Spleen weights as a ratio to baseline bodyweight for sham males (SH‐M), cancer males (CA‐M) [M, Week 1, n = 4; Week 2, n = 4; Week 3, n = 5; end of life (EOL), n = 20], sham females (SH‐F), and cancer females (CA‐F) (F, Week 1, n = 5; Week 2, n = 5; Week 3, n = 6; EOL, n = 17). Data: Weeks 1–3, Experiment 2; EOL, Experiment, 1a and b. (B) Primary tumor (n = 20), liver (n = 24), and spleen (n = 24) weight change to bioluminescence ratio via IVIS luciferin imaging. Data: EOL, Experiment 1a. (C) White blood cell count analysis via impedance analysis (SH‐M, n = 9; SH‐F, n = 10; CA‐M, n = 9; CA‐F, n = 10). Data: EOL, Experiment 1a and b. (D‐F) Cytokines quantification via Luminex fluorophore intensity analysis (n = 9–12/group/time point). Data: Experiment 1a. Data Information: Within and across group differences were analyzed with one‐way ANOVA with Tukey's post hoc with >3 comparisons (A) and Fischer LSD post‐hoc for ≤3 comparisons (B,D‐F). Differences across groups (A,D‐F) or within sexes (C) at each time point were analyzed with unpaired t test. Prior to ANOVA cytokine analysis, robust regression and outlier removal (ROUT) with coefficient Q = 1% was used as non‐physiologic/error values were detected (D‐F). Colors (A,D‐F): CA‐M, blue; CA‐F, red. Data are mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.